STAA · STAAR Surgical Company
$24.71
-2.10% last session
End-of-day data · updated 2026-07-24
Market cap
$1B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
24.5
Dividend yield
—
Beta
1.23
Avg volume
1M
Employees
1K
2D change
-2.10%
5D change
-8.51%
10D change
-11.52%
30D change
-16.36%
60D change
-25.50%
MTD change
-14.07%
YTD change
4.76%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — STAA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-22
Latest call per bank · past 12 months
Wells Fargo
Equal-Weight$25.00
+1.2% vs priceJefferies
Buy$21.50
-13.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-22 | Wedbush | Reiterates | Outperform | $40.00 |
| 2026-07-16 | Wedbush | Reiterates | Outperform | $40.00 |
| 2026-05-29 | Wedbush | Reiterates | Outperform | $40.00 |
| 2026-05-15 | Wells Fargo | Maintains | Equal-Weight | $16.00 → $25.00 |
| 2026-05-14 | Canaccord Genuity | Maintains | Buy | $27.00 → $32.00 |
| 2026-05-14 | Piper Sandler | Maintains | Neutral | $16.00 → $33.00 |
| 2026-05-14 | Stifel | Maintains | Hold | $18.00 → $31.00 |
| 2026-05-14 | Wedbush | Upgrade | Neutral → Outperform | $26.00 → $40.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-23
- RSI (14): RSI is 35 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 16.7% below the 50-day MA ($29.03).
- Price vs 200-day MA: Trading 1.0% below the 200-day MA ($24.43).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.41) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($16.10) and high ($33.34).
STAA Price Chart
Loading chart for STAA…
Fundamentals
About STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
More in Medical Instruments & Supplies
ISRG
Intuitive Surgical, Inc.
$119B -41.4% YTD
MDLN
Medline Inc.
$67B -10.4% YTD
BDX
Becton, Dickinson and Company
$42B 1.6% YTD
ALC
Alcon Inc.
$33B -14.3% YTD
RMD
ResMed Inc.
$28B -19.9% YTD
WST
West Pharmaceutical Services, I
$25B 29.4% YTD
COO
The Cooper Companies, Inc.
$14B -14.3% YTD
SOLV
Solventum Corporation
$13B -2.5% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.